Arrowhead Pharmaceuticals Reports Positive Two-Year Data for Plozasiran

Arrowhead Pharmaceuticals (ARWR) presented two-year efficacy and safety data for plozasiran during the American College of Cardiology's 75th Annual Scientific Session. Crucially, the study confirmed zero adjudicated acute pancreatitis events during the observation period, significantly bolstering the drug's safety profile. The updated data also highlighted specific efficacy in reducing atherogenic lipoproteins, addressing a key cardiovascular risk factor. Following these results, the company announced it is targeting year-end 2026 for its supplemental New Drug Application (sNDA) submission. Analysts believe the combination of sustained clinical performance and a concrete regulatory timeline reduces the risk profile for this lead asset. These findings strengthen the investment case for plozasiran as a durable therapeutic solution for hypertriglyceridemia.

Sources:businesswire.combarchart.commarketscreener.combioworld.comintellectia.aiainvest.cominvesting.comnationaltoday.comwww.pharmiweb.com